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Introduction
Combined antiretroviral therapy (cART) suppresses viral replication 
and improves survival and quality of life for those HIV-1–infected 
patients who can both access and tolerate cART. However, cART is 
not curative and must be continued for life (1–3). The HIV-1 reser-
voir persists indefinitely under suppressive cART, resulting in viral 
rebound in all HIV-1–infected individuals when cART is discon-
tinued. In addition, cART does not fully restore immune function 
and lifelong treatment is associated with substantial side effects 
and non–AIDS related “end-organ diseases”(4). Therefore, there 
is a great need for the development of novel therapies to control or 
eliminate the persistent HIV-1 reservoir and thus reduce the need 
for lifelong cART.
During natural HIV-1 infection, a limited number of individu-
als (termed elite controllers or long-term nonprogressors) remain 
persistently infected for decades without marked depletion of 
CD4+ T cells (5–7). These patients exhibit strong HIV-1–specific 
polyclonal memory CD4+ T cell activity and maintain a highly 
polyfunctional cytotoxic T lymphocyte (CTL) response (8–10). 
The robust HIV-1–specific immune response observed in a large 
majority of these patients has been proposed to explain this natu-
ral functional cure, raising the possibility that therapeutic immu-
nization in infected patients whose viral replication is suppressed 
by cART might result in similar control of viral replication after 
cART discontinuation (11–13).
Therapeutic immunization is intended to enhance the 
immune responses against HIV-1 by vaccination with a suitable 
immunogen. One way to enhance the immunogenicity of proteins 
is to increase their uptake by dendritic cells (DCs), which are spe-
cialized antigen-presenting cells (APCs) (14–16). Targeting DCs by 
fusing antigens to monoclonal antibodies (mAbs) directed against 
internalizing cell-surface receptors can substantially enhance pro-
tein immunogenicity (17–19). We and others have demonstrated 
that targeting HIV-1 Env gp140 or Gag p24 to various DC recep-
tors including DEC-205, LOX-1, Langerin, DCIR, and CD40 
induced potentially protective humoral and cellular immunity in 
both priming and viral vector boost settings (20–23). Recently, 
we tested in both nonhuman primates (NHPs) and in humans an 
epitope-based vaccine composed of 5 HIV-1 peptides which con-
tain multiple and highly conserved T cell epitopes from HIV-1 
Gag, Pol, and Nef that induce HIV-1–specific CD4+ and CD8+ T 
cell responses (24–29). Moreover, we have shown that administra-
tion of these T cell epitopes as HIV-1 lipopeptides either combined 
with a recombinant virus (CanaryPox) or as a component of an ex 
vivo DC therapeutic vaccine strategy, contributed to the control of 
viral replication after cART interruption (27, 30, 31).
CD40 is a potent activating receptor expressed by a range of 
APCs, including DCs (32). Thus, targeting CD40 offers the poten-
Activation of HIV-1 reservoirs and induction of anti–HIV-1 T cells are critical to control HIV-1 rebound after combined 
antiretroviral therapy (cART). Here we evaluated in humanized mice (hu-mice) with persistent HIV-1 infection the therapeutic 
effect of TLR3 agonist and a CD40-targeting HIV-1 vaccine, which consists of a string of 5 highly conserved CD4+ and CD8+ 
T cell epitope-rich regions of HIV-1 Gag, Nef, and Pol fused to the C-terminus of a recombinant anti-human CD40 antibody 
(αCD40.HIV5pep). We show that αCD40.HIV5pep vaccination coadministered with poly(I:C) adjuvant induced HIV-1–specific 
human CD8+ and CD4+ T cell responses in hu-mice. Interestingly, poly(I:C) treatment also reactivated HIV-1 reservoirs. 
When administrated in therapeutic settings in HIV-1–infected hu-mice under effective cART, αCD40.HIV5pep with poly(I:C) 
vaccination induced HIV-1–specific CD8+ T cells and reduced the level of cell-associated HIV-1 DNA (or HIV-1 reservoirs) in 
lymphoid tissues. Most strikingly, the vaccination significantly delayed HIV-1 rebound after cART cessation. In summary, 
the αCD40.HIV5pep with poly(I:C) vaccination approach both activates replication of HIV-1 reservoirs and enhances the anti–
HIV-1 T cell response, leading to a reduced level of cell-associated HIV-1 DNA or reservoirs. Our proof-of-concept study has 
significant implication for the development of CD40-targeting HIV-1 vaccine to enhance anti–HIV-1 immunity and reduce HIV-1 
reservoirs in patients with suppressive cART.
TLR3 agonist and CD40-targeting vaccination induces 
immune responses and reduces HIV-1 reservoirs
Liang Cheng,1,2 Qi Wang,1 Guangming Li,1 Riddhima Banga,3,4 Jianping Ma,1 Haisheng Yu,1 Fumihiko Yasui,1 Zheng Zhang,1,5 
Giuseppe Pantaleo,3,4 Matthieu Perreau,3,4 Sandra Zurawski,6,7 Gerard Zurawski,6,7 Yves Levy,6,8 and Lishan Su1,2
1Lineberger Comprehensive Cancer Center, and 2Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. 3Service of Immunology and 
Allergy and 4Swiss Vaccine Research Institute, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland. 5Research Center for Clinical & Translational Medicine, Beijing 302 Hospital, 
Beijing, China. 6Vaccine Research Institute, Université Paris-Est, Faculté de Médecine, INSERM U955, Créteil, France. 7Baylor Institute for Immunology Research and INSERM U955, Dallas, Texas, USA. 
8Assistance Publique-Hôpitaux de Paris, Groupe Henri-Mondor Albert-Chenevier, Service d’Immunologie Clinique, Créteil, France.
Conflict of interest: GZ, SZ, and YL are named inventors on CD40-targeting vaccine 
patents and patent filings held jointly by INSERM and the Baylor Research Institute.
Submitted: December 4, 2017; Accepted: July 9, 2018.
Reference information: J Clin Invest. 2018;128(10):4387–4396. 
https://doi.org/10.1172/JCI99005.
than CpG-B and R848 for enhancing 
antigen-specific CD4+ and CD8+ 
T cell responses to vaccination in 
hu-mice, which correlated with their 
ability to activate human mDCs and 
induce IL-12 (40). In the present 
study, we tested the therapeutic effi-
cacy of the αCD40.HIV5pep vaccine 
coadministered with the poly(I:C) 
adjuvant in vivo in the hu-mice 
model of persistent HIV-1 infection.
Results
αCD40.HIV5pep plus poly(I:C) vac-
cination elicits HIV-1–specific human 
T cell responses. We and others 
have shown that functional human 
immune systems, including human 
DCs and T cells, are developed in 
immunodeficient mice transplanted 
with human fetal liver–derived 
CD34+ cells and thymus, and these 
hu-mice can initiate T cell immu-
nity in response to infection or vac-
cination (41–46). Hu-mice support 
HIV-1 infection and are proven rel-
evant and robust models to study 
HIV-1 persistence, pathogenesis, 
and therapy (47, 48). In the present 
study, we first tested the immuno-
genicity of the αCD40.HIV5pep 
vaccine in vivo in hu-mice in the 
presence of the toll-like receptor 3 
(TLR3) agonist poly(I:C) as adju-
vant. Poly(I:C) treatment in vivo 
enhanced the expression of CD40 
on human DCs (Figure 1, A and B), which potentially provided 
more binding targets for the αCD40.HIV5pep protein. In addi-
tion, poly(I:C) treatment also elevated the expression levels of 
HLA-DR and the costimulatory molecule CD86 on human DCs, 
which are important for antigen presentation and T cell activation. 
We also found that CD141+ DCs, which are important for cross-
presentation of exogenous protein antigen to CD8+ T cells (49–52), 
were developed in hu-mice and were activated in vivo by poly(I:C) 
treatment (Supplemental Figure 1, A and B; supplemental mate-
rial available online with this article; https://doi.org/10.1172/
JCI99005DS1). Administration of poly(I:C) in vivo also induced 
production of human IL-12 and IFN-α (Supplemental Figure 1C), 
which is important for induction of T cell immune response.
Thus, we vaccinated hu-mice with the αCD40.HIV5pep pro-
tein with poly(I:C) as adjuvant. Ten days after the boost vaccina-
tion, we terminated the mice and detected antigen-specific human 
T cell response by stimulating the splenocytes ex vivo with the 
corresponding pools of 5 HIV-1 long peptides. Without poly(I:C) 
as adjuvant, αCD40.HIV5pep protein vaccination alone did 
not induce a significant level of antigen-specific T cell response 
(Figure 1, C–E). We found that both CD8+ and CD4+ T cells from 
tial advantage of inducing DC maturation and delivery of antigen 
to CD40-induced antigen-specific humoral and cellular immune 
response (33, 34) and protection against tumor (35). In addi-
tion, CD40 targeting has shown superiority for evoking antigen- 
specific CD8+ T cell responses in vitro over targeting other recep-
tors, including DEC-205, DCIR, and LOX-1 (36–38). We have 
fused the above-mentioned 5 HIV-1 peptides to the heavy chain 
C-terminus of a recombinant anti-human CD40 antibody (called
herein αCD40.HIV5pep) (39). The αCD40.HIV5pep can effectively
expand HIV-1 antigen–specific multifunctional helper CD4+ and
cytotoxic CD8+ T cells in HIV-1–infected patient PBMC or autolo-
gous DC/T cell cocultures (39). The expanded polyfunctional cyto-
toxic CD8+ T cells can control HIV-1 replication in vitro (39). In addi-
tion, Toll-like receptor ligand (TLR-L) adjuvants that can activate
and elevate CD40 expression on human APCs (40) may synergisti-
cally enhance the efficacy of the CD40-targeting vaccine. We have 
showed previously that poly(I:C) was superior to other TLR agonist 
adjuvants (CpG-A, CpG-B, CpG-C, R848, R837, MPLA) for induc-
ing human IL-12 production and activating human mDCs both in
vitro and in vivo in humanized mice (hu-mice) (40). Importantly,
we believe we have also proven that poly(I:C) is more efficacious
Figure 1. Poly(I:C) enhances αCD40.HIV5pep vaccination to induce both human CD8+ and CD4+ T cell 
responses in vivo. (A and B) Hu-mice were treated with poly(I:C) (50 μg/mouse, i.p.) or PBS as control. 
Leukocytes from spleen were isolated for flow cytometry analysis 24 hours after treatment. Representative 
histogram (A) and summary data (B) show the expression of CD40, CD86, and HLA-DR on mDCs (hCD45+CD3–
CD19–CD14–CD11c+) after treatment. (B) Representative data from 4 hu-mice per group with mean values ± 
SEM of 3 independent experiments. **P < 0.01, ***P < 0.001 by unpaired, 2-tailed Student’s t test. (C–E) 
Hu-mice were vaccinated with αCD40.HIV5pep with or without poly(I:C) and boosted at week 3. Mice were 
euthanized 10 days after the boost vaccination. Splenocytes from mice were stimulated ex vivo with the 
corresponding 5 specific HIV-1 long peptides plus αCD28 mAb. (C and D) IL-2 and TNF-α expression by CD8+ 
and CD4+ T cells were detected by intracellular staining. Representative plots (C) and summarized data (D) 
show percentages of IL-2– and TNF-α–producing CD8+ T cells CD4+ T cells. (E) IFN-γ production was detected 
by ELISpot assay. (D and E) Combined data from 2 independent experiments with mean values ± SEM (PBS, 
n = 6; αCD40.HIV5pep, n = 6, αCD40.HIV5pep + poly(I:C), n = 6). *P < 0.05, **P < 0.01, ***P < 0.001 by 1-way 
ANOVA and Bonferroni’s post hoc test.
compared with untreated cultures (Figure 3, A and B). Compared 
with the anti-CD3/anti-CD28 mAb, the efficiency of reactivation 
of HIV-1 with poly(I:C) was around 20% at 5 μg/ml, and around 
35% at 10 μg/ml by virus outgrowth assay (Figure 3, C and D). No 
difference was observed on the effect of HIV-1 reservoir reactiva-
tion from resting memory CD4 by poly(I:C) when cocultured with 
autologous CD3-depleted blood mononuclear cells either irradi-
ated or not irradiated, suggesting that HIV-1 RNA was reactivated 
from resting memory CD4+ T cells (Figure 3, A–D). In addition, we 
also stimulated total leukocytes from lymphoid organs of HIV-1–
infected hu-mice under cART ex vivo with poly(I:C) or with other 
TLR agonists. We found that poly(I:C) worked as efficiently as the 
TLR7 agonists R837 and R848 to reactivate HIV-1 RNA (Figure 
3E), whereas CpG-B did not reactivate HIV-1 RNA compared with 
PBS-treated control (Figure 3E). As positive control, the inhibitor 
of histone deacetylases (SAHA) reactivated HIV-1 RNA more effi-
ciently (10.4-fold more than control) than poly(I:C) (2.3-fold more 
than control) (Figure 3E). No change of cell-associated HIV-1 DNA 
was detected after stimulation with TLR agonists, suggesting that 
the increase in cell-associated RNA was due to more active HIV-1 
transcription, but not new infection during the culture (Figure 3F).
In summary, we found that in addition to its adjuvant activity 
in enhancing anti–HIV-1 T cell response to vaccination, poly(I:C) 
can also function as a reservoir-activating agent.
αCD40.HIV5pep with poly(I:C) vaccination rescues anti–HIV-1 T 
cell responses and reduces the size of the HIV-1 reservoir. We have pre-
viously reported that persistent HIV-1 infection in hu-mice led to T 
cell tolerance, and cART treatment rescued the number but not the 
function of T cells (45, 46). We next determined whether αCD40.
HIV5pep plus poly(I:C) vaccination could rescue anti–HIV-1 T cell 
activity in infected hu-mice under cART. Hu-mice infected with 
HIV-1 received cART at 5 weeks postinfection (wpi) through 12 
wpi. Hu-mice were vaccinated 2 times with αCD40.HIV5pep plus 
poly(I:C), at 8 wpi and 11 wpi (Figure 4A). Hu-mice treated with 
PBS or poly(I:C) alone were used as control. We monitored HIV-1 
viremia during the treatment and found that αCD40.HIV5pep 
with poly(I:C) activated the HIV-1 reservoir in the same manner as 
treatment with poly(I:C) treatment alone (Figure 4A). At 12 wpi we 
terminated the hu-mice and determined anti–HIV-1 T cell response 
levels as well as HIV-1 reservoir size in lymphoid organs. Results 
indicated that αCD40.HIV5pep with poly(I:C) rescued the abil-
ity of CD8+ T cells to produce both IFN-γ and TNF-α in response 
to HIV-1 peptide stimulation ex vivo (Figure 4, B and C). The 
IFN-γ– and TNF-α–expressing T cells also coexpressed the CD107a 
marker, signifying their killing ability (Supplemental Figure 3). 
hu-mice vaccinated with poly(I:C) adjuvant produced IL-2 and 
TNF-α (Figure 1, C and D) after HIV-1 peptide, but not irrelevant 
HBV antigen (Supplemental Figure 2) after stimulation ex vivo, 
indicating vaccination-induced, antigen-specific T cell responses. 
T cells from mice vaccinated with poly(I:C) adjuvant also pro-
duced IFN-γ after peptide stimulation ex vivo (Figure 1E). Thus, 
αCD40.HIV5pep plus poly(I:C) vaccination elicits HIV-1–specific 
human T cell responses in vivo.
Poly(I:C) reactivates HIV-1 reservoirs ex vivo in CD4+ T cells from 
HIV-1–infected individuals treated with cART and in vivo in infected 
hu-mice. HIV-1 persists during effective cART in part because its 
genome becomes stably integrated into latently infected cells. 
These latently infected cells do not express viral proteins and 
hence remain invisible to the immune system. We have reported 
before that, as in humans, cART efficiently suppresses HIV-1 repli-
cation in hu-mice, but cells harboring HIV-1 DNA persist (45). It is 
believed that to eliminate the viral reservoir, latent virus in infected 
cells needs to be reactivated to express HIV-1 proteins (53, 54). 
TLR agonists are potential reagents to reactivate HIV-1 expression 
(55–58). Thus, we tested whether the TLR3 agonist poly(I:C), in 
addition to its immune adjuvant activity, can activate the HIV-1 
reservoir in vivo in infected hu-mice under cART. As shown in Fig-
ure 2A, cART treatment suppressed HIV-1 viremia in all infected 
hu-mice within 2 weeks. We treated infected hu-mice with poly(I:C) 
3.5 weeks after initiating cART. Interestingly, poly(I:C) treatment 
in the presence of cART led to low “blips” of HIV-1 viremia within 
3 days, which returned to undetectable levels after 1 week (Figure 
2A). We detected increased levels of cell-associated HIV-1 RNA but 
not cell-associated HIV-1 DNA (Figure 2B) at the time point of virus 
rebound (8.5 weeks after infection), which suggested that the low 
blips of viremia in the plasma under cART were due to more active 
HIV-1 transcription after poly(I:C) treatment.
We further tested whether TLR3 agonist poly(I:C) can reacti-
vate HIV-1 reservoirs in CD4+ T cells from cART-treated, HIV-1–
infected individuals by virus outgrowth assay. We cultured resting 
memory CD4+ T cells of cART-treated individuals with undetect-
able plasma HIV-1 RNA (below 20 copies/ml) with autologous 
CD3-depleted blood mononuclear cells either irradiated or not 
irradiated in the presence of poly(I:C) as previously described 
(59). As controls, cells were stimulated with anti-CD3/anti-CD28 
monoclonal antibody (mAb) (positive control) or left unexposed 
(negative control). Supernatants were collected at day 14 for HIV-1 
RNA detection. The data indicated that poly(I:C) at either 5 μg/
ml or 10 μg/ml induced significant production of HIV-1 RNA from 
5 × 105 resting memory CD4+ T cells in the culture supernatants 
Figure 2. Poly(I:C) treatment activates the HIV-1 reservoir in vivo. (A) Hu-mice 
infected with HIV-1 were treated with cART from 4.5–10.5 weeks postinfection  
(wpi). At 8 wpi, mice were treated with poly(I:C) or PBS as control. Plasma 
HIV-1 genome was detected at the indicated time points. Combined data from 
2 independent experiments with mean values ± SEM are shown. (B) Hu-mice 
were treated as in A. Mice were terminated at 8.5 wpi. Relative cell-associated 
HIV-1 RNA and DNA in human cells from spleens of HIV-1+cART+PBS–treated 
mice (PBS), or HIV-1+cART+poly(I:C)–treated mice (poly(I:C)) were quantified 
by PCR. HIV-1+cART+PBS, n = 4; HIV-1+cART+poly(I:C), n = 5. *P < 0.05 by 
unpaired, 2-tailed Student’s t test.
ure 4, D and E and Table 1). We performed a correlation analysis 
and found that anti–HIV-1 CD8+ and CD4+ T cell responses were 
reversely associated with HIV-1 DNA and RNA levels in different 
lymphoid organs (Supplemental Figure 4). Thus, αCD40.HIV5pep 
with poly(I:C) vaccination, in the presence of cART, enhances anti–
HIV-1 T cell activity and reduces the HIV-1 reservoir.
Hu-mice vaccinated with αCD40.HIV5pep plus poly(I:C) show 
delayed rebound of virus replication after cART interruption. Finally, 
we analyzed the effect of αCD40.HIV5pep plus poly(I:C) vaccina-
tion on HIV-1 rebound after cART discontinuation. Hu-mice with 
persistent HIV-1 infection received cART followed by 2 vaccina-
tions after full suppression of HIV-1 (Figure 5A). We stopped cART 
at 11 wpi (1 week after the last vaccination) and monitored virus 
rebound after cART (Figure 5A). One week after cART cessation 
(12 wpi), HIV-1 rebounded in 14% (1/7) of control-treated and 29% 
Therapeutic vaccination also rescued the ability of CD4+ T cells to 
produce TNF-α in response to stimulation of specific peptides ex 
vivo (Figure 4, B and C). Poly(I:C) treatment alone, although it acti-
vated the HIV-1 reservoir (Figure 4A), did not enhance anti–HIV-1 
T cell activity (Figure 4, B and C).
We next investigated whether therapeutic vaccination reduced 
the HIV-1 reservoir size in infected hu-mice under cART. We found 
that cell-associated HIV-1 DNA was significantly decreased by 7.6-
fold in splenocytes, 10.2-fold in cells from bone marrow, and 13.8-
fold in cells from mesenteric lymph nodes (mLNs) in vaccinated 
hu-mice compared with PBS-treated control hu-mice (Figure 4D 
and Table 1). Cell-associated HIV-1 RNA was also reduced in spleen 
(8-fold), bone marrow (3.6-fold), and mLNs (7-fold) (Figure 4E and 
Table 1). Poly(I:C) treatment alone did not change the HIV-1 res-
ervoir size as detected by cell-associated HIV-1 DNA or RNA (Fig-
Figure 3. Poly(I:C) treatment reactivates HIV-1 production in cART-treated HIV-1–infected individuals. (A–D) Resting memory CD4+ T cells (HLA-DR–
CD25–CD69–) of 3 aviremic ART-treated HIV-1–infected individuals were used for virus outgrowth assay. (A) Proportion of HIV-1 RNA-positive wells induced 
following poly(I:C) treatment. Wells with detectable HIV-1 RNA (≥200 HIV-1 RNA copies/ml) were referred to as HIV-1 RNA-positive wells for the condition 
tested. (B) Levels of HIV-1 RNA copies/ml induced following poly(I:C) treatment. (C) Frequencies of cells containing inducible replication-competent virus 
as measured by RUPM induced upon poly(I:C) treatment. (D) Fraction of poly(I:C)-induced cells containing replication-competent virus as assessed by HIV-1 
RNA as compared with anti-CD3/28. Panels A–B were generated using the 5 replicates of the highest concentration of cells (5 × 105 cells) of all conditions 
by VOA in 3 aviremic cART-treated HIV-1–infected individuals, except the conditions with poly(I:C) at 10 μg/ml, which were generated using 2 aviremic ART-
treated HIV-1–infected individuals. Subjects were color-coded and each color corresponds to a subject (B and C). Histograms correspond to mean (C and D) 
and red bars correspond to SEM (B–D). Red asterisks indicate statistical significance as compared with the unstimulated or unexposed condition (*P < 0.05). 
Anti-CD3/anti-CD28 MAb is represented by 3/28. Statistical significance was obtained using either 2-tailed Chi-square analysis for comparison of positive 
proportions (A) or 1-way ANOVA (Kruskal-Wallis test) followed by Wilcoxon matched-pairs 2-tailed signed rank test (B–D). (E and F) Combined cells from 
spleen, bone marrow, and mLN of cART–treated HIV-1–infected hu-mice were cultured ex vivo with poly(I:C) (5 μg/ml), R848(5 μg/ml), R837(5 μg/ml), CpG-B 
(5 μg/ml), and SAHA (1 μM) in the presence of the antiretroviral drug nevirapine. Each dot represents data from 1 mouse. Relative cell-associated HIV-1 RNA 
(E) and DNA (F) were detected 48 hours after culture. **P < 0.01, ***P < 0.001 by unpaired, 2-tailed Student’s t test.
Targeting of vaccine antigen to DCs is a promising strategy 
for boosting vaccine immunogenicity and inducing protective 
or therapeutic efficacy (18). We have shown before that αCD40.
HIV5pep can effectively expand HIV-1 antigen–specific multifunc-
tional helper CD4+ and cytotoxic CD8+ T cells in the PBMCs of 
HIV-infected patients, and the expanded polyfunctional cytotoxic 
CD8+ T cells can control HIV-1 replication in vitro (39). Here we take 
advantage of hu-mice with functional human immune systems to 
test both the immunogenicity and efficacy of the αCD40.HIV5pep 
vaccine in vivo. We also tested the TLR3 agonist to induce CD40 
expression on DCs to enhance the efficacy of the αCD40.HIV5pep 
vaccine. We found that αCD40.HIV5pep with poly(I:C) vaccina-
tion elicits both functional HIV-1 antigen–specific human CD8+ and 
CD4+ responses in vivo in naive hu-mice. Importantly, when admin-
istrated in a therapeutic setting in cART-suppressed mice, αCD40.
HIV5pep with poly(I:C) vaccination restored the CD8+ T cells to 
produce IFN-γ and TNF-α in response to HIV-1 antigen stimulation. 
Our promising results in hu-mice provide the preclinical rationale to 
test the immunogenicity of the αCD40.HIV5pep vaccine in healthy 
volunteers and the therapeutic benefit of the vaccine to reverse 
anti–HIV-1 T cell function in HIV-1–infected patients.
It has been proposed that HIV-1 therapeutic vaccination should 
be combined with reservoir-activating agents. TLR agonists are 
potent vaccine adjuvants (60) and may also activate the HIV-1 
reservoir or reverse HIV-1 latency (55–57). Whitney et al. recently 
reported that a TLR7 agonist given to SIV-infected ART-suppressed 
Rhesus macaques caused transient increases in the level of plasma 
virus (58). We found here that the TLR3 agonist poly(I:C) treatment 
led to transient production of plasma HIV-1 RNA blips 3 days after 
(2/7) of poly(I:C)-treated hu-mice, but did not rebound in the vac-
cinated hu-mice (Figure 5, B–D and Table 2). By the second week 
(13 wpi), 100% (7/7) of the control-treated and 100% (7/7) of the 
poly(I:C)-treated hu-mice became HIV-1–positive, whereas only 
25% (2/8) of vaccinated hu-mice showed detectable viremia in the 
blood (Figure 5, B–D and Table 2). We detected HIV-1 rebound in 
all vaccinated hu-mice (8/8) by the third week after cART cessation 
(14 wpi); however, the viremia in those hu-mice with rebounded 
HIV-1 was significantly lower in the vaccinated group than in the 
control groups (Figure 5, B–D and Table 2). By the fourth week (15 
wpi), the vaccinated mice still showed lower viral load in the plasma 
compared with the control mice (Figure 5, B–D and Table 2).
Based on the findings described above, we conclude that 
αCD40.HIV5pep with poly(I:C) vaccination rescues anti–HIV-1 T 
cell responses, reduces cART-resistant HIV-1 reservoirs, and leads 
to better control of virus replication after discontinuation of cART.
Discussion
In humans, cART suppresses HIV-1 replication but is not curative 
due to the remarkably long half-life of the HIV-1 reservoir. One 
approach that has generated considerable enthusiasm is com-
bining strategies to induce the production of virus from latently 
infected cells together with interventions that can enhance the 
ability of the host immune system to clear the virus-producing 
cells (53, 54). Using the humanized mouse model of persistent 
HIV-1 infection, we show here that a therapeutic vaccine target-
ing HIV-1 antigens to CD40 combined with poly(I:C) activated 
the cART-resistant HIV-1 reservoir, enhanced anti–HIV-1 T cell 
response, and thereby reduced the HIV-1 reservoir size.
Figure 4. αCD40.HIV5pep plus poly(I:C) therapeutic vaccination rescues anti–HIV-1 T cell responses and reduces the size of HIV-1 reservoirs. Hu-mice 
infected with HIV-1 were treated with cART from 5 wpi to 12 wpi. The mice were vaccinated with αCD40.HIV5pep plus poly(I:C) or treated with poly(I:C) or 
PBS as control at 8 wpi and 11 wpi. Mice were terminated at 12 wpi. (A) Plasma HIV-1 RNA in each group at the indicated time point. (B and C) At termina-
tion, splenocytes from mice were stimulated ex vivo with corresponding 5 specific HIV-1 long peptides plus αCD28 mAb for 8 hours (BFA added at 3 hours). 
Representative plots (B) and summarized data (C) show percentages of IFN-γ+ and TNF-α+ CD8+ and CD4+ T cells. (D) Cell-associated HIV-1 DNA in human 
cells from spleen, bone marrow, and mLNs was quantified by PCR. (E) Relative levels of cell-associated HIV-1 RNA in human cells from spleens, bone 
marrow, and mLNs were quantified by PCR. (A and C–E) Mean ± SEM from 4 mice in each group. *P < 0.05, **P < 0.01, ***P < 0.001 by 1-way ANOVA and 
Bonferroni’s post hoc test.
treatment in HIV-1–infected mice with cART treatment. This result 
indicates that poly(I:C) may work as a reservoir-activating agent 
in vivo. HIV-1 RNA in plasma became undetectable 1 week after 
treatment, probably due to inhibition by cART of reactivated HIV-1 
replication. In addition, we proved that poly(I:C) can reactivate 
HIV-1 RNA from resting memory CD4+ T cells from cART-treated 
patients. Together, our data support the concept that poly(I:C) can 
potentially function as an HIV-1 reservoir–activating agent. The 
advantage of using TLR agonists as reservoir-activating agents is 
that they are also potent vaccine adjuvants, whereas HDAC inhibi-
tors suppress host cellular immune functions (61, 62).
A key observation from our study is that αCD40.HIV5pep 
with poly(I:C) vaccination led to reduction of HIV-1 reservoir size 
in spleen and bone marrow and delayed virus rebound after cART 
discontinuation in HIV-1–infected cART-suppressed hu-mice. Of 
note, poly(I:C) treatment alone failed to reduce the HIV-1 reservoir 
or delay virus rebound, although it activated the HIV-1 reservoir in 
vivo. These data suggest that the anti–HIV-1 T cell response elicited 
or rescued by the vaccination contributed to the reservoir reduc-
tion and virus control after cART interruption. We also observed 
that even though the virus rebounded in all vaccinated mice at 
later time points after stopping cART, the plasma HIV-1 RNA 
levels were lower in vaccinated hu-mice compared with the PBS- 
or poly(I:C)-treated mice, indicating that vaccination enhanced 
virus control. It is important to point out that some cohorts of 
hu-mice that we used were reconstituted with HSCs from HLA-
B57/B58+ donors, which may enhance vaccine responsiveness. It 
will be of interest to compare the relative response to HIV-1 vacci-
nation in hu-mice with HLA-B57/B58+ and HLA-B57/B58– donors 
in future studies. It is also important to state that there are several 
limitations of the humanized mouse model, including short-term 
cART of HIV-1 infection and infection with a molecular clone of 
HIV-1. In addition, the human immunity developed in hu-mice is 
not fully functional as that found in immunocompetent hosts (42, 
47). The lymphoid structures, such as B cell follicles, which have 
been identified as HIV-1 sanctuary sites for HIV-1 reservoir cells 
to escape from CD8+ cell-mediated killing in nonhuman primate 
models (63) and HIV-1–infected people (64), are not fully devel-
oped in hu-mice. The restored anti–HIV-1 T cell immune response 
by vaccination in hu-mice may not be robust enough to eliminate 
or fully control the HIV-1 reservoir. We believe that the effect of 
the vaccination would be better in immunocompetent hosts. We 
believe that our proof-of-concept study in hu-mice has important 
implication for the development of CD40-targeting HIV-1 vaccine 
to cure HIV-1 infection in humans.
Methods
Construction of hu-mice. NRG (NOD-Rag2–/–γc–/–) mice were obtained 
from the Jackson Laboratory. All mice were housed and bred in a spe-
cific pathogen-free environment. Hu-mice were generated as previ-
ously reported (65). Briefly, 6- to 8-week-old NRG mice were suble-
thally irradiated and anesthetized, and 1-mm3 fragments of human 
fetal thymus were implanted under the kidney capsule. CD34+ hema-
topoietic progenitor cells purified from fetal liver of the same donor 
were injected intravenously within 3 hours. Human immune cell 
engraftment was detected by flow cytometry 12 weeks after trans-
plantation. We used different human donors for different cohorts of 
hu-mice in the study.
Production of αCD40.HIV5pep protein and vaccination. Recom-
binant anti-human CD40 antibody fused to 5 HIV peptide regions 
(αCD40.HIV5pep) was produced as previously reported (39), except 
that we humanized the mouse variable regions to reduce antigenic-
ity in humans and relocated 2 of the HIV5pep regions onto the light 
chain C-terminus to improve productivity. These sequences, hAnti-
CD40VH3-LV-hIgG4H-C-Flex-v1-Pepgag17-f1-gag253-f2-nef116-f3 
(GenBank KM660791) and hAnti-CD40VK2-LV-hIgGKC-pol158-
f3-nef66 (GenBank KM660792), were configured in vectors and 
expressed and purified as protein secreted from stably transfected 
Table 1. αCD40.HIV5pep with poly(I:C) vaccination in the presence of cART reduces the size of the HIV-1 reservoir
Donor Mouse no.  Percentage of cell 
(preinfection)
Treatment HIV-1 RNA in plasma (log10) Cell-associated DNA/RNA
CD45
A
CD3
B
5 wpi 8 wpi 8.5 wpi 10 wpi 12 wpi Spleen Bone marrow
DNAC RNAD DNA RNA
1E 2775 67.7 83 PBS 5.2 ND ND ND ND 752 63 76 12
1 2776 80.5 76.8 PBS 6.0 ND ND ND ND 407 76 253 11
1 2777 49.3 75.2 PBS 5.9 ND ND ND ND 551 29 194 9.5
1 2764 65.1 44.9 PBS 5.6 ND ND ND ND 298 32 171 6.6
1 2743 76.3 76.1 Poly(I:C) 5.2 ND 3.7 ND ND 792 45 212 5.6
1 2747 84.3 81.9 Poly(I:C) 5.4 ND 3.3 ND ND 450 21 202 7.9
1 2756 82.1 73.7 Poly(I:C) 6.5 ND ND ND ND 180 67 155 16
1 2757 60.5 72.4 Poly(I:C) 5.7 ND ND ND ND 1043 60 111 7.5
1 2751 39.9 70.9 Vax 5.3 ND ND ND ND 95 6.8 ND 1.0
1 2752 89.9 79.5 Vax 5.6 ND ND ND ND 21 11 33 4.7
1 2754 90.2 80.2 Vax 5.0 ND 3.5 ND ND 129 6.2 35 1.8
1 2755 63.1 75.9 Vax 5.6 ND 3.3 ND ND 85 1.0 ND 3.3
Humanized mice engrafted with human HSC and thymus were treated as in Figure 3A. APercentage of human CD45+ of total cells in PBMCs. BPercentage of 
CD3+ from human CD45+ cells. CValue stands for copies per 106 human cells. DValue stands for relative level as defined in Methods. EDonor HLA class I type: 
HLA-A2–, HLA-B7,27–, HLA-B57,58–. wpi, weeks postinfection. Vax, vaccination with αCD40.HIV5pep+poly(I:C). ND, not detectable.
CHO-S cells as previously described (39). The vaccines had low lipo-
polysaccharide levels of 0.04–0.07 ng/mg protein. For vaccination, 
hu-mice were intramuscularly (half-dose) and intraperitoneally (half-
dose) injected with 10 μg αCD40-HIV5pep alone or coinjected with 
50 μg poly(I:C). Control mice received PBS or poly(I:C) treatment.
HIV-1 infection of hu-mice. The R5 tropic strain of HIV-1 (JR-CSF) 
was generated by transfection of 293T cells with plasmid contain-
ing full-length HIV-1 (JR-CSF) genome. Hu-mice with stable human 
leukocyte reconstitution were anesthetized and infected with HIV-1 
(JR-CSF) (10 ng p24 or 3,000 infectious units per mouse) through 
retro-orbital injection. Both male and female mice were used for all 
the experiments.
Combination antiretroviral therapy (cART). Food formulated 
with antiretroviral individual drugs was prepared as reported with 
elevated dose modifications (66). In brief, tablets of emtricitabine 
and tenofovir disoproxil fumarate (Truvada; Gilead Sciences) and 
raltegravir (Isentress; Merck) were crushed into fine powder and 
manufactured with TestDiet 5B1Q feed (Modified LabDiet 5058 
with 0.12% amoxicillin) into half-inch irradiated pellets. Final 
concentrations of drugs in the food were 4,800 mg/kg raltegravir, 
1,560 mg/kg tenofovir disoproxil, and 1,040 mg/kg emtricitabine. 
The estimated daily drug doses were 768 mg/kg raltegravir, 250 
mg/kg tenofovir disoproxil, and 166 mg/kg emtricitabine.
HIV-1 genomic RNA detection in plasma. HIV-1 RNA was purified 
from the plasma with the QIAampkit Viral RNA Mini Kit (Qiagen). 
The RNA was then reverse transcribed and quantitatively detected 
by real-time PCR using the TaqMan Fast Virus 1-Step PCR kit 
(Thermo Fisher Scientific). The primers used for detecting the HIV 
Gag gene were (5′- GGTGCGAGAGCGTCAGTATTAAG-3′ and 5′- 
AGCTCCCTGCTTGCCCATA-3′). The probe (FAM-AAAATTCG-
GTTAAGGCCAGGGGGAAAGAA-QSY7) used for detection was 
ordered from Applied Biosystems and the reactions were set up 
following manufacturer’s guidelines and were run on the Quant-
Studio 6 Flex PCR system (Applied Biosystems). The detection 
limit of the real-time PCR reaction is 4 copies per reaction. Accord-
ingly, due to the relatively small volume of each bleeding in mice 
(around 50–100 μl total blood), the limit of detection of the assay 
is 400 copies/ml plasma. We set the copy number that is below the 
detectable limit as 1.
Cell-associated HIV-1 DNA detection. To measure total cell- 
associated HIV-1 DNA, nucleic acid was extracted from spleen and 
bone marrow cells using the DNeasy mini kit (Qiagen). HIV-1 DNA 
was quantified by real-time PCR. DNA from serial dilutions of ACH2 
cells, which contain 1 copy of the HIV genome in each cell, was used to 
generate a standard curve.
Cell-associated HIV-1 RNA detection. To measure total cell- 
associated HIV-1 RNA, nucleic acid was extracted from spleen or bone 
marrow cells using the RNeasy plus mini kit (Qiagen). HIV-1 RNA 
was detected as described above. The HIV-1 RNA expression levels 
were normalized to human CD4 mRNA (5′-GGGCTTCCTCCTC-
CAAGTCTT-3′ and CCGCTTCGAGACCTTTGC) controls and the 
result was calculated as fold change in gene expression.
Antigen-specific T cell response detection. For antigen-specific stim-
ulation, splenocytes from vaccinated hu-mice were collected 10 days 
after the second vaccination and stimulated ex vivo with 5 specific 
HIV long peptides (39) plus αCD28 for 12 hours. Brefeldin A was added 
during the last 4 hours of stimulation and IL-2/TNF-α expression by 
CD4+ and CD8+ T cells was detected by intracellular staining. ELISpot 
plates (96-well, Millipore, catalog S2EM004M99) were coated with 
5 μg/ml mouse anti-human IFN-γ antibody (BD Pharmingen) over-
night at 4°C. After blocking with complete RPMI for 2 hours at 37°C, 
5 × 105 splenocytes were stimulated with the corresponding 5 specific 
Figure 5. Hu-mice receiving αCD40.HIV5pep plus poly(I:C) therapeutic vaccination show improved control of HIV-1 replication after cART discontinu-
ation. (A) Schematic diagram of the experimental design. Hu-mice infected with HIV-1 were treated with cART from 4 wpi to 11 wpi. The mice were 
vac cinated with αCD40.HIV5pep plus poly(I:C) or treated with poly(I:C) or PBS as control at 7.5 wpi and 10 wpi. Virus rebound was detected by PCR weekly 
after cART cessation at 11 wpi. (B) Plasma HIV-1 RNA in each group at indicated time points. (C) Kinetic analysis of HIV-1 rebound after cART cessation. (D) 
Plasma HIV-1 RNA at 12, 13, 14, 15 wpi from each mouse in different treatment groups. (B–D) Combined data from 2 independent experiments with mean 
values ± SEM (HIV+cART+PBS, n = 6; HIV+cART+poly(I:C), n = 7; HIV+cART+poly(I:C)+αCD40.HIV5pep, n = 8). *P < 0.05, **P < 0.01, ***P < 0.001. Gehan-
Breslow-Wilcoxon test (C) or 1-way ANOVA and Bonferroni’s post hoc test (D) was performed.
purchased from Beckman Coulter. FITC-conjugated anti–HLA-7,27 and 
biotinylated anti–HLA-57,58 were purchased from One Lamda, Thermo 
Fisher Scientific. Data were analyzed using Summit 4.3 software (Dako).
Sorting of resting memory CD4+ T cells. Cryopreserved blood 
mononuclear cells were thawed, and CD4+ T cells were enriched 
using the EasySep human CD4+ T cell enrichment kit (StemCell 
Technologies). CD4+ T cells were then stained with an Aqua LIVE/
DEAD stain kit (4°C, 15 minutes) and then with anti-CD4–FITC, 
anti-CD45RA–ECD, anti–HLA-DR-PB, anti-CD25–PE-Cy7, and anti-
CD69–PerCp-Cy5.5 (4°C, 25 minutes), and viable resting memory 
(CD4+CD45RA−CD25−CD69−HLA-DR−) CD4+ T cell populations were 
sorted using a FACSAria fluorescence-activated cell sorter (Becton 
Dickinson). In all sorting experiments, the grade of purity of the sorted 
cell populations was greater than 97%.
Viral outgrowth assay (VOA). Different cell concentrations (5-fold 
limiting dilutions: 5 × 105, 105, 2 × 104, and 4 × 103 cells) of sorted viable 
resting memory CD4+ T cells (HLA-DR−CD25−CD69−) of 3 aviremic 
cART-treated HIV-1–infected individuals were cultured with autolo-
gous CD3-depleted blood mononuclear cells (106 cells/ml) irradiated 
or not irradiated in the presence of poly(I:C) (5 or 10 μg/ml) as previ-
ously described (59). As controls, cells were stimulated with anti-CD3/
anti-CD28 mAb–coated plates (10 μg/ml; 72 hours) (positive control) 
or left unexposed (negative control) as previously described (59). All 
cell conditions were cultured in complete RPMI supplemented with 
IL-2 (50 U/ml) for 14 days. Medium was replaced at day 5 and resup-
plemented with cytokines and poly(I:C). Supernatants were collected 
HIV-1 long peptides at 2 μg/ml, while addition of medium served as 
negative control. Plates were incubated at 37°C for 24 hours before 
washing with cold H2O twice and 5 times with PBS containing 0.05% 
(vol/vol) Tween 20. Biotinylated anti-human IFN-γ antibody (BD 
Pharmingen) was added at 1 μg/ml for 1 hour at 37°C and, after wash-
ing, a 1:1,000 dilution of Avidin-HRP (BD Pharmingen) was added for 
1 hour at 37°C. After final washing, stable final substrate solution AEC 
(3-amino-9-ethylcarbazole) (BD Pharmingen) was added to the plate, 
incubated for 15 minutes at room temperature, and then the reaction 
was stopped by thorough rinsing with water. After drying, the num-
ber of spots in each well was counted with an automated ELISpot plate 
reader (CTL Immunospot).
Flow cytometry. For surface staining, single-cell suspensions pre-
pared from spleens of hu-mice were stained with surface markers and 
analyzed on a CyAn ADP (Dako). For intracellular cytokine staining, 
cells were first stained with surface markers and then permeabilized 
with cytofix/cytoperm buffer (BD Bioscience), followed by intracellu-
lar staining. FITC-conjugated anti-human CD40, PE-conjugated anti-
human CD107a, CD141, PE/Cy5-conjugated anti-human CD4, CD86, 
CD1c, PE/Cy7-conjugated anti-human CD3, HLA-DR, PB-conjugated 
anti-human CD4, CD14, IL-2, APC-conjugated anti-human CD11c, 
TNF-α and APC/Cy7-conjugated anti-human CD45, and PE-conjugated 
anti-human HLA-A2 were purchased from Biolegend. Pacific orange– 
conjugated anti-mouse CD45, PE/Texas red–conjugated anti-human 
CD3, CD8, and LIVE/DEAD Fixable Aqua (LD7) Dead Cell Stain Kit 
were purchased from Invitrogen. FITC-conjugated anti–HIV-1 p24 was 
Table 2. αCD40.HIV5pep with poly(I:C) vaccination in the presence of cART delays HIV-1 rebound after cART cessation
Donor Mouse no.  Percentage of cell 
(preinfection)
Treatment HIV-1 RNA in plasma (log10)
CD45
A
CD3
B
4 wpi 7 wpi 8 wpi 11 wpi 12 wpi 13 wpi 14 wpi 15 wpi
2 C 1527 58 72.3 PBS 4.8 ND ND ND ND 5.1 5.3 5.2
2 1534 41 74.6 PBS 5.1 ND ND ND 3.9 6.6 6.0 6.0
2 1537 76.8 30.7 PBS 4.5 ND ND ND ND 5.9 5.9 5.9
2 1529 23.9 29.8 Poly(I:C) 5.3 ND 3.7 ND 3.9 5.1 5.3 5.2
2 1531 48.1 57.7 Poly(I:C) 4.4 ND 3.3 ND ND 5.7 5.6 5.4
2 1533 33.5 56.9 Poly(I:C) 4.8 ND ND ND ND 6.4 6.1 6.5
2 1515 54.3 17.5 Vax 4.3 ND ND ND ND ND 5.1 5.3
2 1518 75.2 49.7 Vax 5.0 ND ND ND ND 5.1 4.8 5.6
2 1525 41.1 69.9 Vax 3.5 ND 3.5 ND ND ND 5.2 5.0
2 1526 63.4 82.2 Vax 5.3 ND 3.3 ND ND ND 4.4 5.6
3 D 1703 35.6 51.8 PBS 5.3 ND ND ND ND 6.2 6.2 6.3
3 1704 28.9 34.6 PBS 4.9 ND ND ND ND 5.7 5.6 6.6
3 1705 60.4 69.5 PBS 5.4 ND ND ND ND 5.7 6.2 6.2
3 1706 55.6 40.9 PBS 5.0 ND ND ND ND 5.1 6.4 6.7
3 1707 28.5 61.5 Poly(I:C) 5.4 ND 3.0 ND ND 6.2 6.7 6.5
3 1708 27.1 61.7 Poly(I:C) 5.3 ND ND ND ND 5.7 6.6 6.9
3 1720 60.6 56.6 Poly(I:C) 5.2 ND ND ND 3.1 5.7 7.7 7.7
3 1721 34.0 48.7 Poly(I:C) 5.5 ND 3.3 ND ND 5.1 5.9 5.8
3 1711 56.6 62.9 Vax 5.3 ND ND ND ND ND 5.2 5.3
3 1714 25.5 65.8 Vax 4.3 ND 3.1 ND ND ND 4.3 4.0
3 1715 27.2 35.5 Vax 5.3 ND ND ND ND 3.2 6.9 7.0
3 1717 50.9 59.7 Vax 5.1 ND ND ND ND ND 4.7 4.9
Humanized mice engrafted with human HSC and thymus were treated as in Figure 4A. APercentage of human CD45+ of total cells in PBMCs. BPercentage of 
CD3+ from human CD45+ cells. CDonor HLA class I type: HLA-A2+, HLA-B7,27–, HLA-B57,58+. DDonor HLA class I type: HLA-A2+, HLA-B7,27–, HLA-B57,58+. wpi, 
weeks post HIV-1 infection. ND, not detectable. Vax, vaccination with αCD40.HIV5pep plus poly(I:C).
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